Pfizer, Innovent Biologics sign $10.5bn cancer drug development deal

Pfizer and Innovent Biologics have signed a global licensing and collaboration agreement worth up to $10.5bn for the research and development of a portfolio of 12 early-stage cancer medicines.

Raccontata damorningstar.combiopharmadive.comthehindubusinessline.comasia.nikkei.comcnbc.comscmp.combenzinga.compharmaceutical-technology.comstartmag.itendpoints.newsqz.com